RON Inhibitors Block MSP Pathway to Treat Bone Loss
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for bone metastases and osteoporosis are inadequate in addressing the complex interactions between tumor cells and the bone microenvironment, particularly the role of the RON ligand, macrophage-stimulating protein (MSP), which drives osteolysis and bone destruction.
Innovation Solution
Administering RON inhibitors, such as OSI-296 and ASLAN002, to target the MSP/RON pathway, thereby inhibiting osteolysis and treating osteoporosis by reducing bone turnover and osteoclast activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies for bone metastases and osteoporosis are used, then bone loss can be partially addressed, but they are inadequate in addressing the complex interactions between tumor cells and the bone microenvironment, particularly the role of the MSP/RON pathway
Solution Approach 1:
The patent extracts and targets the specific MSP/RON pathway from the complex bone microenvironment interactions. By using RON inhibitors (such as OSI-296 and ASLAN002) that specifically block the RON receptor tyrosine kinase, the therapy isolates and addresses this particular pathological pathway without being limited by the complexity of other interactions in the bone microenvironment.
Solution Approach 2:
The patent changes the therapeutic parameter from general bone protection to specific RON pathway inhibition. By introducing small molecule inhibitors that bind to and inhibit RON receptor tyrosine kinase activity, the therapy transforms the approach from addressing bone loss symptoms to blocking the specific molecular parameter (RON signaling) that drives osteolysis in bone metastases and osteoporosis.
2Object-affected harmful factors
If RON inhibitors are administered to block the MSP/RON pathway, then bone destruction and osteoclast activity are reduced, but this represents a novel therapeutic approach that differs from existing RANKL or TGFβ signaling therapies
Solution Approach 1:
The patent introduces RON inhibitors as intermediary molecules that mediate between the MSP/RON pathway and osteoclast activity. These small molecule inhibitors act as intermediaries that bind to the RON receptor tyrosine kinase, blocking its signaling function and thereby preventing the downstream effects that lead to increased osteoclast activity and bone destruction, without directly affecting osteoclasts themselves.
3Adaptability or versatility
If the MSP/RON pathway is blocked independently of RANKL or TGFβ signaling, then a novel therapeutic approach is achieved, but this requires targeting a specific pathway that is distinct from established therapies
Solution Approach 1:
The patent segments the bone disease therapeutic targets into distinct signaling pathways. By focusing specifically on the MSP/RON pathway and using RON inhibitors that selectively target this pathway, the therapy divides the complex disease process into manageable, pathway-specific components. This segmentation allows for independent targeting of RON signaling separate from RANKL or TGFβ pathways, enabling precise therapeutic intervention.
Data Source
AI summary
Provided herein are methods for inhibiting osteolysis or treating osteoporosis in a subject in need thereof, the method including administering to the subject at least one RON inhibitor. The osteolysis may be caused by a condition selected from the group consisting of cancer, inflammation, and cyst. The condition may include a bone tumor or a tumor located in bone. The subject may have been diagnosed with bone cancer. The inhibitor may be ASLAN002. The inhibitor may be OSI-296. The inhibitor may be selective or specific for RON. The inhibitor may not depend on the function of RANKL or TGFβ.